- Home
- MIRM vs SIG Comparison
MIRM vs SIG Comparison
Compare MIRM & SIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | SIG |
|---|---|---|
| Founded | 2018 | 1950 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.4B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | MIRM | SIG |
|---|---|---|
| Price | $79.34 | $82.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 7 |
| Target Price | $92.45 | ★ $108.14 |
| AVG Volume (30 Days) | 809.5K | ★ 1.0M |
| Earning Date | 11-04-2025 | 12-02-2025 |
| Dividend Yield | N/A | ★ 1.54% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.42 |
| Revenue | $471,794,000.00 | ★ $6,821,100,000.00 |
| Revenue This Year | $53.78 | $2.26 |
| Revenue Next Year | $19.91 | $1.58 |
| P/E Ratio | ★ N/A | $24.25 |
| Revenue Growth | ★ 53.66 | N/A |
| 52 Week Low | $36.88 | $45.55 |
| 52 Week High | $82.58 | $110.20 |
Technical Indicators
Market Signals| Indicator | MIRM | SIG |
|---|---|---|
| Relative Strength Index (RSI) | 62.33 | 38.12 |
| Support Level | $77.99 | $81.56 |
| Resistance Level | $82.58 | $87.58 |
| Average True Range (ATR) | 3.21 | 2.79 |
| MACD | 1.03 | 0.14 |
| Stochastic Oscillator | 83.25 | 12.00 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About SIG Signet Jewelers Limited
Signet Jewelers Ltd is a retailer of diamond jewelry. Its merchandise mix includes bridal, fashion, watches, and others. The bridal category includes engagement, wedding and anniversary purchases. Its segments are the North America segment, the International segment, and the Other segment. The North America segment contributes to the majority of the revenue. The North America segment generates revenue from Mall and Off-Mall & Outlet.